- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04170218
Quality of Care for Knee and Hip Osteoarthritis in Elderly Patients (QSAMISA)
Quality of Care for Knee and Hip Osteoarthritis in Elderly Patients: a Multicentric Observational Study in France Using Quality Indicators Assessed by Questionnaire
Introduction: Hip and knee osteoarthritis (OA) was ranked in 2010 as the eleventh highest contributor to global disability. In France in 2014, non-spinal OA was the leading self-reported cause of morbidity among adults over sixty-five years of age, with a prevalence of 49.5 per cent. OA is known to be the first cause of disability in activities of daily life and a risk factor of frailty among people over seventy-five years of age. Despite its major impact on the elderly population's quality of life and health, quality of care for OA in elderly patients remains understudied.
Objective: The study aims to assess the quality of care for knee and hip OA in patients aged 75 years and over.
Study Overview
Status
Detailed Description
Study Type
Enrollment (Anticipated)
Contacts and Locations
Study Locations
-
-
-
Créteil, France, 94010
- Assistance Publique Hôpitaux de Paris - CHU HENRI MONDOR
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- patients aged seventy-five years or over
- with symptomatic hip or knee osteoarthritis according to the American College of Rheumatology criteria
- with pain for more than three months
- affiliated to French social security
- having given their oral non-opposition to participate (or oral non-opposition of the guardian in case of legal guardianship)
Exclusion Criteria:
- clinical or radiological sign suggesting a differential diagnosis for hip or knee pain
- acute disease with clinical repercussion on walking
- life-threatened patients
Study Plan
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
number of participants referred to an orthopedic surgeon as assessed by ACOVE's quality indicator questionnaire
Time Frame: at enrollment
|
at enrollment
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
rate of eligible patients who passed the quality indicator about annual assessment of functional status and degree of pain, assessed by questionnaire
Time Frame: at enrollment
|
The eligibility criterion is answer "yes" to the question "Do you have pain in your joints that bothers you a lot on most days?".
The pass criterion is a "yes" response to either of the two questions "In the past 12 months, has any doctor or nurse asked you about the severity of your joint pain?" "In the past 12 months, has any doctor or nurse asked you if your joint pain affects the things you like or need to do?".
The rate is calculated using the numerator as the number of eligible patients who passed the quality indicator and the denominator as the number of patients eligible for the quality indicator.
|
at enrollment
|
|
rate of eligible patients who passed the quality indicator about exercise therapy for patients with newly diagnosed knee osteoarthritis, assessed by questionnaire
Time Frame: at enrollment
|
The eligibility criteria are knee pain that had lasted at least 3 months, health did not limit the patient's ability to bathe or dress, and patients or surrogates indicated that the patient did not have severe dementia.
The pass criterion is a "yes" response to the question "Have you ever been sent to physical therapy or an exercise group or class for your knee pain?".
The rate is calculated using the numerator as the number of eligible patients who passed the quality indicator and the denominator as the number of patients eligible for the quality indicator
|
at enrollment
|
|
rate of eligible patients who passed the quality indicator about education regarding the natural history, treatment, and self- management of osteoarthritis, assessed by questionnaire
Time Frame: at enrollment
|
The eligibility criterion is pain in any joint lasting at least 6 months.
The pass criterion is a a "yes" response to at least 1 of the 3 questions "Has any doctor or nurse ever talked to you about what your arthritis or joint pain will be like as time goes on, or the natural history of arthritis?"
"Has any doctor or nurse ever talked to you about how to keep your arthritis or joint pain from getting worse?"
"Has any doctor or nurse ever talked to you about how your arthritis can be treated?".
The rate is calculated using the numerator as the number of eligible patients who passed the quality indicator and the denominator as the number of patients eligible for the quality indicator.
|
at enrollment
|
|
rate of eligible patients who passed the quality indicator about acetaminophen as first-line pharmacologic therapy, assessed by questionnaire
Time Frame: at enrollment
|
The eligibility criterion is a "yes" response to the question "Has any doctor or nurse recommended any treatments for your joint pain?".
The pass criterion is a "yes" response to the question "Did any doctor or nurse recommend you try acetaminophen before other medications for your joint pain?".
Trade names of acetaminophen are mentioned to help participants.
The rate is calculated using the numerator as the number of eligible patients who passed the quality indicator and the denominator as the number of patients eligible for the quality indicator.
|
at enrollment
|
|
rate of eligible patients who passed the quality indicator about advising patients treated with non-steroidal anti-inflammatory drugs (NSAIDs) of their risks, assessed by questionnaire
Time Frame: at enrollment
|
The eligibility criteria are NSAID on medication list, or a "yes" response to the question "Do you take any medications like aceclofenac, celecoxib, diclofenac, etoricoxib, ibuprofene, indometacine, ketoprofene, naproxene or piroxicam ?
These medications are known as non-steroidal anti-inflammatory drugs".
Corresponding trade names are mentioned to help participants.
The pass criterion is a "yes" response to the question "Did any doctor or nurse or pharmacist tell you about the possible side effects or risks from taking this medication?".
The rate is calculated using the numerator as the number of eligible patients who passed the quality indicator and the denominator as the number of patients eligible for the quality indicator.
|
at enrollment
|
|
rate of eligible patients who passed the quality indicator about offering prophylaxis with a proton-pump inhibitor or misoprostol to patients treated with non-selective NSAIDs, assessed by questionnaire
Time Frame: at enrollment
|
The eligibility criteria are NSAID on medication list, or a "yes" response to the question "Do you take any medications like aceclofenac, diclofenac, ibuprofene, indometacine, ketoprofene, naproxene or piroxicam?".
Corresponding trade names are mentioned to help participants.
The pass criterion is a "yes" response to the question "Did any doctor or nurse recommend you take another medication to protect your stomach or intestines or from developing an ulcer?
For example omeprazole, esomeprazole, pantoprazole, lansoprazole or misoprostol".
Corresponding trade names are mentioned to help participants.
The rate is calculated using the numerator as the number of eligible patients who passed the quality indicator and the denominator as the number of patients eligible for the quality indicator.
|
at enrollment
|
|
percentage of patients taking non-steroidal anti-inflammatory drugs for their hip or knee osteoarthritis, assessed by questionnaire and reading current medical prescription
Time Frame: at enrollment
|
at enrollment
|
|
|
percentage of patients taking opioid analgesics for their hip or knee osteoarthritis, assessed by reading current medical prescription
Time Frame: at enrollment
|
at enrollment
|
|
|
percentage of patients taking symptomatic slow-acting anti-arthritics, assessed by assessed by reading current medical prescription
Time Frame: at enrollment
|
at enrollment
|
|
|
percentage of patients taking non-steroidal anti-inflammatory topically applied, assessed by assessed by reading current medical prescription
Time Frame: at enrollment
|
at enrollment
|
|
|
percentage of patients treated with intra-articular infiltration of corticosteroid, assessed by questionnaire
Time Frame: at enrollment
|
at enrollment
|
|
|
percentage of patients treated with intra-articular infiltration of visco-supplementation, assessed by questionnaire
Time Frame: at enrollment
|
at enrollment
|
|
|
percentage of patients who consulted a rheumatologist for their knee or hip osteoarthritis, assessed by questionnaire
Time Frame: at enrollment
|
at enrollment
|
|
|
percentage of patients who beneficiate from a modification of their medical prescription related to their knee or hip osteoarthritis treatment during or after their stay in the inclusion geriatric department, assessed by reading the medical record
Time Frame: after the patient discharge
|
after the patient discharge
|
|
|
percentage of patients referred to an orthopedic surgeon during or after their stay in the inclusion geriatric department, assessed by reading the medical record
Time Frame: after the patient discharge
|
after the patient discharge
|
|
|
percentage of patients referred to an orthopedic surgeon who really consulted the orthopedic surgeon, assessed by calling the patient one year after inclusion
Time Frame: one year after inclusion
|
one year after inclusion
|
|
|
percentage of patients referred to an orthopedic surgeon who beneficiated from a joint replacement for their hip or knee, assessed by calling the patient one year after inclusion
Time Frame: one year after inclusion
|
one year after inclusion
|
|
|
vital status at one year
Time Frame: one year after inclusion
|
one year after inclusion
|
Collaborators and Investigators
Investigators
- Study Director: Jean-Philippe David, PhD
Study record dates
Study Major Dates
Study Start (Anticipated)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- APHP190201
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Knee Osteoarthritis
-
Istanbul University - CerrahpasaCompletedKnee Osteoarthritis | Knee Osteoarthritis (Knee OA)Turkey (Türkiye)
-
Edin MešanovićCompletedOsteoarthritis | Osteoarthritis of the Knee | Osteoarthritis of Knee | Osteoarthritis of the Knees | Osteoarthritis (OA) of the Knee | Osteoarthritis Knee | Osteoarthritis in the Knee | Osteoarthritis of Knee JointBosnia and Herzegovina
-
Golden Jubilee National HospitalJohnson & Johnson; DePuy OrthopaedicsNot yet recruitingOsteoarthritis | Knee Osteoarthritis | Osteoarthritis (OA) | Osteo Arthritis | Osteoarthritis in the Knee | Osteoarthritis (Knee) | Osteo Arthritis of the KneeUnited Kingdom
-
Dr. David WassersteinSunnybrook Research InstituteRecruitingKnee Osteoarthritis (Knee OA) | Knee Osteoarthritis (OA)Canada
-
LifeBridge HealthMicroPort Orthopedics Inc.; Rubin Institute for Advanced OrthopedicsRecruitingKnee Osteoarthritis | Osteoarthritis, Knee | Knee Pain Chronic | Arthropathy of Knee Joint | Knee Disease | Osteoarthritis Knees Both | Osteoarthritis Knee Left | Osteoarthritis Knee RightUnited States
-
Lucas R. Cusumano, MDNot yet recruitingKnee Osteoarthritis | Knee Discomfort | Knee Pain Chronic | Knee Swelling PainUnited States
-
Emory UniversityVertex Pharmaceuticals IncorporatedNot yet recruitingKnee Osteoarthritis | Knee ArthritisUnited States
-
VA Office of Research and DevelopmentNot yet recruitingKnee Osteoarthritis (Knee OA)United States
-
The Hong Kong Polytechnic UniversityChinese University of Hong Kong; Zhujiang HospitalNot yet recruitingKnee Osteoarthritis (Knee OA)
-
University of MiamiNot yet recruiting